The words don't seem to align with the numbers!!!!
The announcement released on the 31st of July infers that Recce has done all of the work/tests required to lodge their IND application with the FDA.
However the 4C estimates a further $774K to be spent on R&D in the next quarter.
This spend cannot relate to the clinical trials as these can only occur after the IND is granted.
I believe that the spend must therefore relate to pre-clinical tests. The amount forecast is the highest yet by Recce in any quarter so far.
So there must still be a long way to go to IND? Despite "BEING ON TRACK" !!!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |